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Abstract: Artemisinin-based combination therapies (ACTs) have become the mainstay for malaria
treatment in almost all malaria endemic settings. Artemisinin derivatives are highly potent and
fast acting antimalarials; but they have a short half-life and need to be combined with partner
drugs with a longer half-life to clear the remaining parasites after a standard 3-day ACT regimen.
When introduced, ACTs were highly efficacious and contributed to the steep decrease of malaria over
the last decades. However, parasites with decreased susceptibility to artemisinins have emerged in
the Greater Mekong Subregion (GMS), followed by ACTs’ failure, due to both decreased susceptibility
to artemisinin and partner drug resistance. Therefore, there is an urgent need to strengthen and
expand current resistance surveillance systems beyond the GMS to track the emergence or spread
of artemisinin resistance. Great attention has been paid to the spread of artemisinin resistance over
the last five years, since molecular markers of decreased susceptibility to artemisinin in the GMS
have been discovered. However, resistance to partner drugs is critical, as ACTs can still be effective
against parasites with decreased susceptibility to artemisinins, when the latter are combined with
a highly efficacious partner drug. This review outlines the different mechanisms of resistance and
molecular markers associated with resistance to partner drugs for the currently used ACTs. Strategies
to improve surveillance and potential solutions to extend the useful therapeutic lifespan of the
currently available malaria medicines are proposed.
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1. Background
The emergence and spread of Plasmodium falciparum parasites with decreased susceptibility to
artemisinin derivatives, and subsequent treatment failures after treatment with artemisinin-based
combination therapies (ACTs) in the Greater Mekong Subregion (GMS) have raised concerns about
the loss of the only highly-effective treatment currently available to treat malaria [1,2]. Artemisinin
resistance, defined as delayed parasite clearance following treatment with conventional ACT regimens,
has been associated with pfKelch13 mutations in the GMS, and several mutations have been validated
as molecular markers of artemisinin resistance in that region [3,4]. Artemisinin resistance may have
spread or emerged in Eastern India, where delayed parasite clearance combined with a high rate of
parasite survival in the ring survival assay (RSA) and the presence of certain pfKelch13 mutations have
been observed [5]. Moreover, some pfKelch13 mutations associated with delayed parasite clearance
have been also reported in South America [6,7] and Papua New Guinea [8]. Nevertheless, different
pfKelch13 mutations have been observed in Africa, but these were not associated with artemisinin
resistance [9–11]. The mode of action of artemisinins is still not fully understood, even though
artemisinin derivatives have been shown to cause oxidative stress and are probably impacting on
multiple targets in the parasite, definitely implying a more complex resistance mechanism associated
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with different determinants other than pfKelch13 [12,13]. Therefore, there is a possibility that parasites
with decreased artemisinin susceptibility are already present in some places in Africa, and are
circulating at low levels, due to the still high multiplicity of infections in this region, and the related
semi-immunity in older individuals [14]. Moreover, partner drugs do play a role in parasite clearance,
even though to a lesser extent than artemisinin derivatives, but their decreased efficacy is probably
affecting parasite clearance, as well [15]. In fact, even though artemisinin derivatives are highly potent
antimalarials that can reduce parasite biomass very quickly [16]; due to their short half-life, they need
to be combined with partner drugs with long half-life to clear the remaining parasites after a 3-day
ACT treatment course [17]. Indeed, ACT failure is not only due to artemisinin resistance, but also to
the failure of partner drugs [18,19]. There are currently five ACTs recommended by the World Health
Organization (WHO): artesunate-sulfadoxine-pyrimethamine (ASSP), artemether-lumefantrine (AL),
dihydroartemisinin-piperaquine (DP), artesunate-amodiaquine (ASAQ), and artesunate-mefloquine
(ASMQ) [20]. Artesunate-pyronaridine (ASPY) is now listed under the WHO’s Model List of Essential
Medicines, and previous restrictions due to concerns about its hepatotoxicity effects have been
removed [21,22]. In this review, the development of resistance to ACTs is discussed and strategies
to improve antimalarial drug resistance surveillance systems that should pay the same attention
to partner drug resistance are proposed, as partner drug resistance may exist or occur even before
resistance to artemisinins emerges in high endemic settings.
2. Mechanisms of Resistance to Partner Drugs
2.1. Lumefantrine
Artemether-lumefantrine (AL) is the most widely used antimalarial in endemic countries.
In 2017, it was estimated that it accounted for almost 75% of all procured quality-assured ACTs [23].
The mode of action of lumefantrine is not well understood, and its main target remains unresolved,
even though it is thought to interfere with hem detoxification [24], or to directly inhibit pfmdr1 [25].
Some recent reports have shown a decreased efficacy of AL in Angola [26,27], Gambia and Malawi [28];
however, so far no convincing evidence of lumefantrine resistance has been reported from the field [29].
Moreover, it has been shown recently in Angola that efficacy was higher when the full treatment course
was directly observed [30]. Decreased susceptibility to lumefantrine (LUM) has been associated with
gene copy number variations (CNV) in pfmdr1 [31] and the wild type pfcrt (K76) and pfmdr1 (N86)
that confer increased susceptibility to chloroquine [32–34]. However, large meta-analyses failed to
find a correlation between pfmdr1 CNV and treatment failure, but confirmed the association with of
pfcrt K76 and pfmdr-1 N86 polymorphisms [35,36]. Moreover, laboratory selection of LUM resistant
parasites has shown that multiple protein transporters may be involved in LUM resistance [37],
and other investigations have shown that pfmrp1 was associated with decreased susceptibility to LUM
in vitro [38].
2.2. Amodiaquine
The combination of artesunate and amodiaquine (ASAQ) is the second most used ACT in malaria
endemic settings. In 2017, it was estimated to account for >20 % of all good quality delivered ACTs [23].
Furthermore, amodiaquine (AQ) is used in combination with sulfadoxine-pyrimethamine (SP) for
seasonal malaria chemoprevention in the Sahel region [39]. The mode of action of AQ is similar to
chloroquine; the drug accumulates in the digestive vacuole where it binds the toxic hem, preventing its
formation into the inert form hemozoin [40]. AQ resistance has been associated with point mutations
in the pfcrt and pfmdr1 genes, and the same mutations as those for chloroquine resistance (pfcrt 76T and
pfmdr1 86Y) have been shown to be the main determinant of decrease susceptibility to AQ in vitro and
in vivo [34,41,42]. However, a specific pfcrt haplotype of codons 72 to 76 (SVMNT) has been associated
with resistance to AQ, but to a lesser degree of resistance to chloroquine [43–45].
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2.3. Piperaquine
The combination of dihydroartemisinin and piperaquine (DP) has proven to be an efficacious
treatment in most malaria endemic settings [46], and is used for treatment in some countries
in Southeast Asia and Africa [47]. Dihydroartemisinin and Piperaquine are also increasingly
considered for malaria prevention in pregnancy [48,49], and for mass drug administration (MDA)
in near-elimination settings in Africa [50–52]. However, DP is failing in the sub-Mekong region
due to resistance to piperaquine (PQ) and decreased susceptibility to artemisinin derivatives [53,54].
Treatment failure with DP was first observed in Western Cambodia, where the cumulative risk of
treatment failure increased from 9.2 % to 24.1% between 2008 and 2010 [18]. The mode of action of
PQ was initially linked to the inhibition of one or more steps in the hemoglobin degradation pathway,
but it is not yet fully understood [55,56]. More recently, PQ resistance has been associated with CNV
in plasmepsin II and III [57] and point mutations in pfcrt [56,58,59]. As the classic in vivo assays have
shown limitations in the assessment of phonotypical resistance to PQ, a piperaquine survival assay
(PSA) has been established to assess changes in parasite strains’ susceptibility to PQ [57]. The presence
of different parasite populations with different mechanisms of resistance to PQ is intriguing and
warrants further investigations to elucidate this pleiotropic mechanism of resistance [59].
2.4. Sulfadoxine-Pyrimethamine
Despite widespread resistance to sulfadoxine-pyrimethamine (SP) in most malaria endemic
settings, the combination artesunate and SP (ASSP) is still used in a few countries for malaria
treatment [47] and intermittent preventive treatment in pregnancy (IPTp) [49], and in combination
with amodiaquine for seasonal malaria chemoprevention (SMC) [39]. Sulfadoxine and pyrimethamine
are inhibiting two enzymes involved the folate biosynthesis pathway; dihydropteroate synthase DHPS
and dihydrofolate reductase DHFR, respectively [60,61]. Resistance to sulfadoxine and pyrimethamine
is by far the best characterized mechanism of resistance; it is associated with point mutations in the
pfdhps and pfdhfr genes, respectively [62,63]. Indeed, the accumulation of point mutations in both
genes is associated with increasing levels of resistance to the combination of the two drugs, with the
combination of the triple mutant in pfdhfr (51I, 59R, 108N) and the double mutant in pfdhps (437G and
540E) being associated with an increased risk of in vivo treatment failure. This quintuple mutant
has been shown to have emerged in Southeast Asia before it spread to other malaria endemic areas,
notably Africa [64,65]. The presence of the quintuple mutation is used to guide treatment policy for
intermittent preventive treatment in infants (IPTi): WHO is recommending not to use IPTi in areas
where the pfdhps 540E mutation (a surrogate marker for the presence of the pfdhfr/pfdhps quintuple
mutant) does exceed 50% [66].
2.5. Mefloquine
The combination of artesunate and mefloquine (ASMQ) was the first ACT that has been introduced
in Southeast Asia to stop resistance to mefloquine (MQ) monotherapy in the early 1990s [67].
Since, the use of this combination has historically been restricted to Southeast Asia, the Pacific
region and South America, but was not used in Africa. With increasing levels of resistance to
MQ and decreased susceptibility to artemisinin derivatives, the combination is now used only in
a few countries [47]. The mode of action of MQ is still unclear, but the drug may inhibit hem
detoxification [24,68], or directly inhibit pfmdr1 [69]. Mefloquine resistance has been associated
with CNV in pfmdr1 [70,71], and polymorphisms in pfmrp1 and pfmrp2 could also potentiate MQ
resistance [38,72,73]. More recently, the cytoplasmic ribosome (pf80S) of the asexual blood-stage
parasite has been suggested as the main target of MQ [74].
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2.6. Pyronaridine
The combination of artesunate and pyronaridine (ASPY) is not yet recommended by the WHO,
but has received a positive opinion from the European Medical Agency (EMA) under article 58 [21].
Moreover, the product was added to the WHO’s Model List of Essential Medicines (EML) and Model
List of Essential Medicines for Children (EMLc) in 2017, and is the only ACT indicated for the blood
stage treatment of both P. falciparum and P. vivax [22]. The combination has shown high efficacy
in Africa where its efficacy was non-inferior to AL and DP [75,76], and in Eastern Cambodia [77].
However, the efficacy of the combination has been shown to be low in Western Cambodia, probably
due to artemisinin resistance and potential cross-resistance between pyronaridine (PY) and PQ [78].
The exact mode of action of PY is not well known; however, the drug is thought to interfere with the
hemozoin formation [79]. To date, resistance to PY has not been reported, but ex vivo assessment has
shown an association between decreased susceptibility to PY and the 76T mutation in pfcrt [80].
3. Discussion
The emergence and spread of parasites with decreased susceptibility to artemisinins is a major
threat to malaria control and elimination. Monitoring antimalarial drug efficacy and resistance is of
paramount importance to maintain the gains made over the last decades in reducing malaria burden
and mortality. Surveillance systems using molecular markers of resistance should become standard
practice, as they are easy to implement and can offer more updated information to complement the
often sparse and outdated data from therapeutic efficacy studies. Indeed, molecular markers can
provide useful information to policymakers, allowing them anticipating treatment efficacy changes
over time, and eventually decide on treatment policy change before resistance translates to clinical
failures. However, molecular surveillance should not only focus on artemisinin resistance, but also on
partner drug resistance.
Our understanding of the mode of action and mechanisms of resistance, even though still
incomplete, has substantially improved, and validated molecular markers can be used to track the
emergence and spread of resistance to antimalarial drugs, as well as to predict clinical efficacy or failure.
For instance, CQ withdrawal in most of Africa lead to the re-emergence of CQ sensitive parasites
with the expansion of wild-type pfcrt K76 that ultimately resulted in CQ efficacy restoration [81,82].
The fact that the two major ACTs in Africa (i.e., ASAQ and AL) were selecting in opposite directions
on the pfmdr1 and pfcrt genes [35,83] resulted in increasing efficacy of ASAQ in areas of high AL usage,
where the efficacy of the latter was declining [34]. However, mechanisms of resistance may differ
from one area to another: Whilst the restoration of CQ efficacy was associated with the return of the
wild-type pfcrt K76 in Africa [82], restoration of CQ efficacy in French Guiana was associated with a
new mutation in pfcrt (350R), with the 76T mutation remaining fixed in the parasite population [84].
Likewise, resistance to PQ has been associated with an elevated copy number of the plasmepsin II and
III gens [54,57]; however, other studies have shown that PQ resistance was mediated through single
nucleotide polymorphisms (SNPs) in pfcrt [56,58,59] making the molecular surveillance of PQ resistance
more complex. Therefore, surveillance systems should not only aim at detecting known and validated
molecular markers, but also at tracking any new genotypes that could be associated with antimalarial
drug resistance. Whole genome sequencing (WGS) could be used in routine surveillance through
regional reference laboratories with respective capacities [85,86] for defining potential new markers
that, in turn, would be validated by in vitro phenotypic assays and/or gene editing techniques.
In high transmission settings, parasites are more exposed to sub-therapeutic drug concentrations
of the long half-life partner drugs, thus increasing the chances of developing resistance [87].
The introduction of aggressive chemoprevention methods such as seasonal malaria chemoprevention
(SMC) and mass drug administration (MDA) will put even more pressure on partner drugs [88,89].
The presence of parasites with decreased susceptibility to artemisinin derivatives does not necessarily
lead to ACT treatment failure, as evidenced with a recent report from Myanmar, where despite high
prevalence of pfKelch13 mutations associated with delayed parasite clearance, AL retains its high
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clinical efficacy [90]. However, resistance to the partner drug would immediately lead to ACT failure,
as with the current 3-day ACT regimen, the short half-life of artemisinin derivatives could not sustain
the efficacy of the combination on its own [91,92]. Hence, molecular surveillance in high transmission
settings should aim at using more sensitive techniques such as amplicon deep sequencing that can
also detect minority variants potentially present in the parasite population [93–95], this could help
to earlier predict the emergence and spread of resistant parasites, allowing policymakers to develop
alternative treatment strategies, before resistance translates into clinical treatment failures.
Currently, there is no alternative to ACTs, even though the antimalarial drug pipeline is
promising [96,97]. Strategies are needed to prolong the useful therapeutic lifespan of the current
malaria medicines, including 1) extending the duration of the current 3-day regimen of ACTs [90,98,99];
2) increasing the dose of the partner drugs [100,101]; 3) using triple combination therapies, with two
partner drugs selecting in opposite directions [36,102,103]; and 4) utilizing multiple first-line
treatments [36]. However, those may be solutions to preserve the efficacy of ACTs in the short- or
medium-term only, as there is already some evidence of parasites developing resistance to two partner
drugs and the artemisinin component at the same time [104,105]. The development of nano-based
drug formulations is another strategy to fight drug resistance by improving drug targeting and
dosing [106–108]. More resources should also be allocated to study the mode of action and mechanisms
of resistance to new antimalarial drugs. Not only will this allow the discovery of new molecular
markers for resistance surveillance, but also pave the way for the development of new drugs with
different modes of action.
The emergence and spread of artemisinin resistance are a major threat to the current efforts to
control and eliminate malaria. Molecular markers are valuable tools for monitoring antimalarial drug
resistance, and need to be fully integrated in routine surveillance, especially for partner drugs in high
endemic settings, where resistance to partner drugs may emerge before resistance to artemisinin.
Funding: This research received no external funding.
Conflicts of Interest: The author declares no conflict of interest.
References
1. Menard, D.; Dondorp, A. Antimalarial Drug Resistance: A Threat to Malaria Elimination. Cold Spring Harb.
Perspect. Med. 2017, 7, a025619. [CrossRef] [PubMed]
2. Woodrow, C.J.; White, N.J. The clinical impact of artemisinin resistance in Southeast Asia and the potential
for future spread. FEMS Microbiol. Rev. 2017, 41, 34–48. [CrossRef] [PubMed]
3. Ariey, F.; Witkowski, B.; Amaratunga, C.; Beghain, J.; Langlois, A.-C.; Khim, N.; Kim, S.; Duru, V.; Bouchier, C.;
Ma, L.; et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 2014, 505, 50–55.
[CrossRef] [PubMed]
4. Ménard, D.; Khim, N.; Beghain, J.; Adegnika, A.A.; Shafiul-Alam, M.; Amodu, O.; Rahim-Awab, G.;
Barnadas, C.; Berry, A.; Boum, Y.; et al. A Worldwide Map of Plasmodium falciparum K13-Propeller
Polymorphisms. N. Eng. J. Med. 2016, 374, 2453–2464. [CrossRef] [PubMed]
5. Das, S.; Saha, B.; Hati, A.K.; Roy, S. Evidence of Artemisinin-Resistant Plasmodium falciparum Malaria in
Eastern India. N. Engl. J. Med. 2018, 379, 1962–1964. [CrossRef] [PubMed]
6. Chenet, S.M.; Akinyi Okoth, S.; Huber, C.S.; Chandrabose, J.; Lucchi, N.W.; Talundzic, E.; Krishnalall, K.;
Ceron, N.; Musset, L.; Macedo de Oliveira, A.; et al. Independent Emergence of the Plasmodium falciparum
Kelch Propeller Domain Mutant Allele C580Y in Guyana. J. Infect. Dis. 2016, 213, 1472–1475. [CrossRef]
[PubMed]
7. Mathieu, L.; Cox, H.; Early, A.M.; Ade, M.-P.; Lazrek, Y.; Grant, Q.; Lucchi, N.W.; Udhayakumar, V.; Seme
Fils, A.J.; Fidock, D.A.; et al. Artemisinin resistance and the pfk13 C580Y mutation in Guyana: A confirmed
link and emergence. In Proceedings of the ASTMH Annual Meeting, New Orleans, LA, USA, 28 October–1
November 2018.
8. Prosser, C.; Meyer, W.; Ellis, J.; Lee, R. Resistance screening and trend analysis of imported falciparum
malaria in NSW, Australia (2010 to 2016). PLoS ONE 2018, 13, e0197369. [CrossRef]
Trop. Med. Infect. Dis. 2019, 4, 26 6 of 11
9. Taylor, S.M.; Parobek, C.M.; DeConti, D.K.; Kayentao, K.; Coulibaly, S.O.; Greenwood, B.M.; Tagbor, H.;
Williams, J.; Bojang, K.; Njie, F.; et al. Absence of putative artemisinin resistance mutations among Plasmodium
falciparum in Sub-Saharan Africa: A molecular epidemiologic study. J. Infect. Dis. 2015, 211, 680–688. [CrossRef]
10. Kamau, E.; Campino, S.; Amenga-Etego, L.; Drury, E.; Ishengoma, D.; Johnson, K.; Mumba, D.; Kekre, M.;
Yavo, W.; Mead, D.; et al. K13-propeller polymorphisms in Plasmodium falciparum parasites from
sub-Saharan Africa. J. Infect. Dis. 2015, 211, 1352–1355. [CrossRef]
11. Apinjoh, T.O.; Mugri, R.N.; Miotto, O.; Chi, H.F.; Tata, R.B.; Anchang-Kimbi, J.K.; Fon, E.M.; Tangoh, D.A.;
Nyingchu, R.V.; Jacob, C.; et al. Molecular markers for artemisinin and partner drug resistance in natural
Plasmodium falciparum populations following increased insecticide treated net coverage along the slope of
mount Cameroon: Cross-sectional study. Infect. Dis. Poverty 2017, 6, 136. [CrossRef]
12. Mbengue, A.; Bhattacharjee, S.; Pandharkar, T.; Liu, H.; Estiu, G.; Stahelin, R.V.; Rizk, S.S.; Njimoh, D.L.;
Ryan, Y.; Chotivanich, K.; et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum
malaria. Nature 2015, 520, 683–687. [CrossRef] [PubMed]
13. Tilley, L.; Straimer, J.; Gnädig, N.F.; Ralph, S.A.; Fidock, D.A. Artemisinin Action and Resistance in
Plasmodium falciparum. Trends Parasitol. 2016, 32, 682–696. [CrossRef] [PubMed]
14. MalariaGEN Plasmodium falciparum Community Project. Genomic epidemiology of artemisinin resistant
malaria. Elife 2016, 5, e08714. [CrossRef] [PubMed]
15. WWARN Parasite Clearance Study Group, W.P.C.S.; Abdulla, S.; Ashley, E.A.; Bassat, Q.; Bethell, D.;
Björkman, A.; Borrmann, S.; D’Alessandro, U.; Dahal, P.; Day, N.P.; et al. Baseline data of parasite clearance
in patients with falciparum malaria treated with an artemisinin derivative: An individual patient data
meta-analysis. Malar. J. 2015, 14, 359. [CrossRef] [PubMed]
16. White, N.J. Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives. Trans. R. Soc.
Trop. Med. Hyg. 1994, 88 (Suppl. 1), 41–43. [CrossRef]
17. Nosten, F.; White, N.J. Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med.
Hyg. 2007, 77, 181–192. [CrossRef] [PubMed]
18. Leang, R.; Barrette, A.; Bouth, D.M.; Menard, D.; Abdur, R.; Duong, S.; Ringwald, P. Efficacy of
dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium
vivax in Cambodia, 2008 to 2010. Antimicrob. Agents Chemother. 2013, 57, 818–826. [CrossRef] [PubMed]
19. Saunders, D.L.; Vanachayangkul, P.; Lon, C. Dihydroartemisinin–Piperaquine Failure in Cambodia. N. Engl.
J. Med. 2014, 371, 484–485. [CrossRef]
20. WHO. WHO|Guidelines for the Treatment of Malaria, 3rd ed.; World Health Organization: Geneva, Switzerland,
2015; p. 316.
21. EMEA. Assessment Report Pyramax Pyronaridine Tetraphosphate/Artesunate Procedure No.: EMEA/H/W/002319;
EMEA: London, UK, 2012; p. 123.
22. MMV Pyramax® (Pyronaridine-Artesunate). Available online: https://www.mmv.org/access/products-
projects/pyramax-pyronaridine-artesunate (accessed on 23 January 2019).
23. UNITAID. Global Malaria Diagnostic and Artemisinin Treatment Commodities Demand Forecast (Phase 2);
UNITAID: Geneva, Switzerland, 2018; p. 89.
24. Combrinck, J.M.; Mabotha, T.E.; Ncokazi, K.K.; Ambele, M.A.; Taylor, D.; Smith, P.J.; Hoppe, H.C.; Egan, T.J.
Insights into the Role of Heme in the Mechanism of Action of Antimalarials. ACS Chem. Biol. Biol.
2013, 8, 133–137. [CrossRef]
25. Martin, R.E.; Shafik, S.H.; Richards, S.N. Mechanisms of resistance to the partner drugs of artemisinin in the
malaria parasite. Curr. Opin. Pharmacol. 2018, 42, 71–80. [CrossRef]
26. Plucinski, M.M.; Talundzic, E.; Morton, L.; Dimbu, P.R.; Macaia, A.P.; Fortes, F.; Goldman, I.; Lucchi, N.;
Stennies, G.; MacArthur, J.R.; et al. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine
for treatment of uncomplicated malaria in children in Zaire and Uíge Provinces, angola. Antimicrob. Agents
Chemother. 2015, 59, 437–443. [CrossRef] [PubMed]
27. Plucinski, M.M.; Dimbu, P.R.; Macaia, A.P.; Ferreira, C.M.; Samutondo, C.; Quivinja, J.; Afonso, M.;
Kiniffo, R.; Mbounga, E.; Kelley, J.S.; et al. Efficacy of artemether–lumefantrine, artesunate–amodiaquine,
and dihydroartemisinin–piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in
Angola, 2015. Malar. J. 2017, 16, 62. [CrossRef]
28. WHO. World Malaria Report 2017; WHO: Geneva, Switzerland, 2017; p. 196.
Trop. Med. Infect. Dis. 2019, 4, 26 7 of 11
29. Hamed, K.; Kuhen, K. No robust evidence of lumefantrine resistance. Antimicrob. Agents Chemother.
2015, 59, 5865–5866. [CrossRef] [PubMed]
30. Davlantes, E.; Dimbu, P.R.; Ferreira, C.M.; Florinda Joao, M.; Pode, D.; Félix, J.; Sanhangala, E.;
Andrade, B.N.; dos Santos Souza, S.; Talundzic, E.; et al. Efficacy and safety of artemether–lumefantrine,
artesunate–amodiaquine, and dihydroartemisinin–piperaquine for the treatment of uncomplicated
Plasmodium falciparum malaria in three provinces in Angola, 2017. Malar. J. 2018, 17, 144. [CrossRef]
[PubMed]
31. Sidhu, A.B.S.; Uhlemann, A.-C.; Valderramos, S.G.; Valderramos, J.-C.; Krishna, S.; Fidock, D.A.
Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine,
lumefantrine, halofantrine, quinine, and artemisinin. J. Infect. Dis. 2006, 194, 528–535. [CrossRef] [PubMed]
32. Sisowath, C.; Strömberg, J.; Mårtensson, A.; Msellem, M.; Obondo, C.; Björkman, A.; Gil, J.P. In Vivo Selection
of Plasmodium falciparum pfmdr1 86N Coding Alleles by Artemether-Lumefantrine (Coartem). J. Infect.
Dis. 2005, 191, 1014–1017. [CrossRef] [PubMed]
33. Sisowath, C.; Petersen, I.; Veiga, M.I.; Mårtensson, A.; Premji, Z.; Björkman, A.; Fidock, D.A.; Gil, J.P. In vivo
selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after
treatment with artemether-lumefantrine in Africa. J. Infect. Dis. 2009, 199, 750–757. [CrossRef] [PubMed]
34. Yeka, A.; Kigozi, R.; Conrad, M.D.; Lugemwa, M.; Okui, P.; Katureebe, C.; Belay, K.; Kapella, B.K.;
Chang, M.A.; Kamya, M.R.; et al. Artesunate/Amodiaquine Versus Artemether/Lumefantrine for the
Treatment of Uncomplicated Malaria in Uganda: A Randomized Trial. J. Infect. Dis. 2016, 213, 1134–1142.
[CrossRef] [PubMed]
35. Venkatesan, M.; Gadalla, N.B.; Stepniewska, K.; Dahal, P.; Nsanzabana, C.; Moriera, C.; Price, R.N.;
Mårtensson, A.; Rosenthal, P.J.; Dorsey, G.; et al. Polymorphisms in Plasmodium falciparum chloroquine
resistance transporter and multidrug resistance 1 genes: Parasite risk factors that affect treatment outcomes
for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am. J. Trop. Med. Hyg.
2014, 91, 833–843. [CrossRef] [PubMed]
36. Okell, L.C.; Reiter, L.M.; Ebbe, L.S.; Baraka, V.; Bisanzio, D.; Watson, O.J.; Bennett, A.; Verity, R.; Gething, P.;
Roper, C.; et al. Emerging implications of policies on malaria treatment: Genetic changes in the Pfmdr-1
gene affecting susceptibility to artemether-lumefantrine and artesunate-amodiaquine in Africa. BMJ Glob.
Health 2018, 3, e000999. [CrossRef] [PubMed]
37. Mwai, L.; Diriye, A.; Masseno, V.; Muriithi, S.; Feltwell, T.; Musyoki, J.; Lemieux, J.; Feller, A.; Mair, G.R.;
Marsh, K.; et al. Genome wide adaptations of Plasmodium falciparum in response to lumefantrine selective
drug pressure. PLoS ONE 2012, 7, e31623. [CrossRef] [PubMed]
38. Veiga, M.I.; Ferreira, P.E.; Jörnhagen, L.; Malmberg, M.; Kone, A.; Schmidt, B.A.; Petzold, M.; Björkman, A.;
Nosten, F.; Gil, J.P. Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated
with major ACT antimalarial drug resistance. PLoS ONE 2011, 6, e20212. [CrossRef] [PubMed]
39. Coldiron, M.E.; Von Seidlein, L.; Grais, R.F. Seasonal malaria chemoprevention: Successes and missed
opportunities. Malar. J. 2017, 16, 481. [CrossRef] [PubMed]
40. Kaur, K.; Jain, M.; Reddy, R.P.; Jain, R. Quinolines and structurally related heterocycles as antimalarials. Eur.
J. Med Chem. 2010, 45, 3245–3264. [CrossRef] [PubMed]
41. Duraisingh, M.T.; Drakeley, C.J.; Muller, O.; Bailey, R.; Snounou, G.; Targett, G.A.; Greenwood, B.M.;
Warhurst, D.C. Evidence for selection for the tyrosine-86 allele of the pfmdr 1 gene of Plasmodium falciparum
by chloroquine and amodiaquine. Parasitology 1997, 114 Pt 3, 205–211. [CrossRef]
42. Holmgren, G.; Gil, J.P.; Ferreira, P.M.; Veiga, M.I.; Obonyo, C.O.; Björkman, A. Amodiaquine resistant
Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. Infect. Genet.
Evol. 2006, 6, 309–314. [CrossRef] [PubMed]
43. Sá, J.M.; Twu, O.; Hayton, K.; Reyes, S.; Fay, M.P.; Ringwald, P.; Wellems, T.E. Geographic patterns
of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and
chloroquine. Proc. Natl. Acad. Sci. USA 2009, 106, 18883. [CrossRef] [PubMed]
44. Sa, J.M.; Twu, O. Protecting the malaria drug arsenal: Halting the rise and spread of amodiaquine resistance
by monitoring the PfCRT SVMNT type. Malar. J. 2010, 9, 374. [CrossRef]
45. Beshir, K.; Sutherland, C.J.; Merinopoulos, I.; Durrani, N.; Leslie, T.; Rowland, M.; Hallett, R.L. Amodiaquine
resistance in Plasmodium falciparum malaria in Afghanistan is associated with the pfcrt SVMNT allele at
codons 72 to 76. Antimicrob. Agents Chemother. 2010, 54, 3714–3716. [CrossRef]
Trop. Med. Infect. Dis. 2019, 4, 26 8 of 11
46. WorldWide Antimalarial Resistance Network (WWARN) DP Study Group. The effect of dosing regimens on
the antimalarial efficacy of dihydroartemisinin-piperaquine: A pooled analysis of individual patient data.
PLoS Med. 2013, 10, e1001564.
47. WHO. World Malaria Report 2018; WHO: Geneva, Switzerland, 2018; p. 210.
48. Kakuru, A.; Jagannathan, P.; Muhindo, M.K.; Natureeba, P.; Awori, P.; Nakalembe, M.; Opira, B.; Olwoch, P.;
Ategeka, J.; Nayebare, P.; et al. Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
N. Engl. J. Med. 2016, 374, 928–939. [CrossRef] [PubMed]
49. Desai, M.; Hill, J.; Fernandes, S.; Walker, P.; Pell, C.; Gutman, J.; Kayentao, K.; Gonzalez, R.; Webster, J.;
Greenwood, B.; et al. Prevention of malaria in pregnancy. Lancet Infect. Dis. 2018, 18, e119–e132. [CrossRef]
50. Eisele, T.P.; Bennett, A.; Silumbe, K.; Finn, T.P.; Chalwe, V.; Kamuliwo, M.; Hamainza, B.; Moonga, H.;
Kooma, E.; Chizema Kawesha, E.; et al. Short-term Impact of Mass Drug Administration with
Dihydroartemisinin Plus Piperaquine on Malaria in Southern Province Zambia: A Cluster-Randomized
Controlled Trial. J. Infect. Dis. 2016, 214, 1831–1839. [CrossRef] [PubMed]
51. Mwesigwa, J.; Achan, J.; Affara, M.; Wathuo, M.; Worwui, A.; Muhommed, N.I.; Kanuteh, F.; Prom, A.;
Dierickx, S.; di Tanna, G.L.; et al. Mass drug administration with dihydroartemisinin-piperaquine and
malaria transmission dynamics in The Gambia—A prospective cohort study. Clin. Infect. Dis. 2018.
[CrossRef] [PubMed]
52. Guler, J.L.; Rosenthal, P.J. Mass drug administration to control and eliminate malaria in Africa: How do we
best utilize the tools at hand? Clin. Infect. Dis. 2018. [CrossRef] [PubMed]
53. Amaratunga, C.; Lim, P.; Suon, S.; Sreng, S.; Mao, S.; Sopha, C.; Sam, B.; Dek, D.; Try, V.; Amato, R.; et al.
Dihydroartemisinin–piperaquine resistance in Plasmodium falciparum malaria in Cambodia: A multisite
prospective cohort study. Lancet Infect. Dis. 2016, 16, 357. [CrossRef]
54. Amato, D.R.; Lim, P.; Miotto, O.; Amaratunga, C.; Dek, D.; Pearson, R.D.; Almagro-Garcia, J.; Neal, A.T.;
Sreng, S.; Suon, S.; et al. Genetic markers associated with dihydroartemisinin–piperaquine failure in
Plasmodium falciparum malaria in Cambodia: A genotype-phenotype association study. Lancet Infect. Dis.
2017, 17, 164–173. [CrossRef]
55. Davis, T.M.E.; Hung, T.-Y.; Sim, I.-K.; Karunajeewa, H.A.; Ilett, K.F. Piperaquine. Drugs 2005, 65, 75–87.
[CrossRef]
56. Dhingra, S.K.; Redhi, D.; Combrinck, J.M.; Yeo, T.; Okombo, J.; Henrich, P.P.; Cowell, A.N.; Gupta, P.;
Stegman, M.L.; Hoke, J.M.; et al. A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum
Resistance to the First-Line Partner Drug Piperaquine. MBio 2017, 8, e00303-17. [CrossRef]
57. Witkowski, B.; Duru, V.; Khim, N.; Ross, L.S.; Saintpierre, B.; Beghain, J.; Chy, S.; Kim, S.; Ke, S.; Kloeung, N.;
et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: A phenotype–genotype
association study. Lancet Infect. Dis. 2017, 17, 174–183. [CrossRef]
58. Agrawal, S.; Moser, K.A.; Morton, L.; Cummings, M.P.; Parihar, A.; Dwivedi, A.; Shetty, A.C.; Drabek, E.F.;
Jacob, C.G.; Henrich, P.P.; et al. Association of a Novel Mutation in the Plasmodium falciparum Chloroquine
Resistance Transporter with Decreased Piperaquine Sensitivity. J. Infect. Dis. 2017, 216, 468–476. [CrossRef]
[PubMed]
59. Ross, L.S.; Dhingra, S.K.; Mok, S.; Yeo, T.; Wicht, K.J.; Kümpornsin, K.; Takala-Harrison, S.; Witkowski, B.;
Fairhurst, R.M.; Ariey, F.; et al. Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum
resistance to the first-line antimalarial piperaquine. Nat. Commun. 2018, 9, 3314. [CrossRef] [PubMed]
60. Cowman, A.F.; Morry, M.J.; Biggs, B.A.; Cross, G.A.; Foote, S.J. Amino acid changes linked to pyrimethamine
resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc. Natl.
Acad. Sci. USA 1988, 85, 9109–9113. [CrossRef] [PubMed]
61. Wang, P.; Read, M.; Sims, P.F.G.; Hyde, J.E. Sulfadoxine resistance in the human malaria parasite Plasmodium
falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated
with folate utilization. Mol Microbiol. 1997, 23, 979–986. [CrossRef] [PubMed]
62. Plowe, C.V.; Cortese, J.F.; Djimde, A.; Nwanyanwu, O.C.; Watkins, W.M.; Winstanley, P.A.; Estrada-Franco, J.G.;
Mollinedo, R.E.; Avila, J.C.; Cespedes, J.L.; et al. Mutations in Plasmodium falciparum dihydrofolate reductase
and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance.
J. Infect. Dis. 1997, 176, 1590–1596. [CrossRef]
Trop. Med. Infect. Dis. 2019, 4, 26 9 of 11
63. Wang, P.; Lee, C.S.; Bayoumi, R.; Djimde, A.; Doumbo, O.; Swedberg, G.; Dao, L.D.; Mshinda, H.; Tanner, M.;
Watkins, W.M.; et al. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of
dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse
origins. Mol. Biochem Parasitol. 1997, 89, 161–177. [CrossRef]
64. Naidoo, I.; Roper, C. Mapping “partially resistant”, “fully resistant”, and “super resistant” malaria. Trends
Parasitol. 2013, 29, 505–515. [CrossRef]
65. Roper, C.; Pearce, R.; Nair, S.; Sharp, B.; Nosten, F.; Anderson, T. Intercontinental Spread of
Pyrimethamine-Resistant Malaria. Science 2004, 305, 1124. [CrossRef]
66. WHO. WHO Policy Recommendation on Intermittent Preventive Treatment during Infancy with
Sulphadoxine-Pyrimethamine (IPTi-SP) for Plasmodium falciparum Malaria Control in Africa; World Health
Organization: Geneva, Switzerland, 2010; p. 3.
67. Looareesuwan, S.; Kyle, D.E.; Viravan, C.; Vanijanonta, S.; Wilairatana, P.; Charoenlarp, P.; Canfield, C.J.;
Webster, H.K. Treatment of patients with recrudescent falciparum malaria with a sequential combination of
artesunate and mefloquine. Am. J. Trop. Med. Hyg. 1992, 47, 794–799. [CrossRef]
68. Fitch, C.D. Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs. Life Sci.
2004, 74, 1957–1972. [CrossRef]
69. Cowman, A.F.; Galatis, D.; Thompson, J.K. Selection for mefloquine resistance in Plasmodium falciparum is
linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc. Natl. Acad.
Sci. USA 1994, 91, 1143–1147. [CrossRef] [PubMed]
70. Wilson, C.M.; Volkman, S.K.; Thaithong, S.; Martin, R.K.; Kyle, D.E.; Milhous, W.K.; Wirth, D.F. Amplification
of pfmdr1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand.
Mol. Biochem. Parasitol. 1993, 57, 151–160. [CrossRef]
71. Price, R.N.; Uhlemann, A.-C.; Brockman, A.; McGready, R.; Ashley, E.; Phaipun, L.; Patel, R.; Laing, K.;
Looareesuwan, S.; White, N.J.; et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1
gene copy number. Lancet 2004, 364, 438–447. [CrossRef]
72. Veiga, M.I.; Osório, N.S.; Ferreira, P.E.; Franzén, O.; Dahlstrom, S.; Lum, J.K.; Nosten, F.; Gil, J.P. Complex
polymorphisms in the Plasmodium falciparum multidrug resistance protein 2 gene and its contribution to
antimalarial response. Antimicrob. Agents Chemother. 2014, 58, 7390–7397. [CrossRef] [PubMed]
73. Woodland, J.G.; Hunter, R.; Smith, P.J.; Egan, T.J. Chemical Proteomics and Super-resolution Imaging Reveal
That Chloroquine Interacts with Plasmodium falciparum Multidrug Resistance-Associated Protein and Lipids.
ACS Chem. Biol. 2018, 13, 2939–2948. [CrossRef]
74. Wong, W.; Bai, X.-C.; Sleebs, B.E.; Triglia, T.; Brown, A.; Thompson, J.K.; Jackson, K.E.; Hanssen, E.;
Marapana, D.S.; Fernandez, I.S.; et al. Mefloquine targets the Plasmodium falciparum 80S ribosome to
inhibit protein synthesis. Nat. Microbiol. 2017, 2, 17031. [CrossRef]
75. Sagara, I.; Beavogui, A.H.; Zongo, I.; Soulama, I.; Borghini-Fuhrer, I.; Fofana, B.; Camara, D.; Somé, A.F.;
Coulibaly, A.S.; Traore, O.B.; et al. Safety and efficacy of re-treatments with pyronaridine-artesunate in African
patients with malaria: A substudy of the WANECAM randomised trial. Lancet Infect. Dis. 2016, 16, 189–198.
[CrossRef]
76. West African Network for Clinical Trials of Antimalarial Drugs (WANECAM), T.W.A.N. for C.T. of A.D.
Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated
treatment of uncomplicated malaria: A randomised, multicentre, open-label, longitudinal, controlled, phase
3b/4 trial. Lancet 2018, 391, 1378–1390. [CrossRef]
77. Leang, R.; Mairet-Khedim, M.; Chea, H.; Huy, R.; Khim, N.; Mey Bouth, D.; Dorina Bustos, M.; Ringwald, P.;
Witkowski, B. Efficacy and safety of pyronaridine-artesunate plus single-dose primaquine for the treatment
of uncomplicated Plasmodium falciparum malaria in eastern Cambodia. Antimicrob. Agents Chemother. 2019.
[CrossRef]
78. Leang, R.; Canavati, S.E.; Khim, N.; Vestergaard, L.S.; Borghini Fuhrer, I.; Kim, S.; Denis, M.B.; Heng, P.;
Tol, B.; Huy, R.; et al. Efficacy and Safety of Pyronaridine-Artesunate for Treatment of Uncomplicated
Plasmodium falciparum Malaria in Western Cambodia. Antimicrob. Agents Chemother. 2016, 60, 3884–3890.
[CrossRef]
79. Auparakkitanon, S.; Chapoomram, S.; Kuaha, K.; Chirachariyavej, T.; Wilairat, P. Targeting of hematin by the
antimalarial pyronaridine. Antimicrob. Agents Chemother. 2006, 50, 2197–2200. [CrossRef]
Trop. Med. Infect. Dis. 2019, 4, 26 10 of 11
80. Madamet, M.; Briolant, S.; Amalvict, R.; Benoit, N.; Bouchiba, H.; Cren, J.; Pradines, B.; French National Centre
for Imported Malaria Study Group. The Plasmodium falciparum chloroquine resistance transporter is associated
with the ex vivo P. falciparum African parasite response to pyronaridine. Parasit. Vectors 2016, 9, 77. [CrossRef]
[PubMed]
81. Laufer, M.K.; Thesing, P.C.; Eddington, N.D.; Masonga, R.; Dzinjalamala, F.K.; Takala, S.L.; Taylor, T.E.;
Plowe, C.V. Return of Chloroquine Antimalarial Efficacy in Malawi. N. Engl. J. Med. 2006, 355, 1959–1966.
[CrossRef] [PubMed]
82. Laufer, M.K.; Takala-Harrison, S.; Dzinjalamala, F.K.; Stine, O.C.; Taylor, T.E.; Plowe, C. V Return of
chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites.
J. Infect. Dis. 2010, 202, 801–808. [CrossRef] [PubMed]
83. Humphreys, G.S.; Merinopoulos, I.; Ahmed, J.; Whitty, C.J.M.; Mutabingwa, T.K.; Sutherland, C.J.;
Hallett, R.L. Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum
mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob. Agents Chemother.
2007, 51, 991–997. [CrossRef] [PubMed]
84. Pelleau, S.; Moss, E.L.; Dhingra, S.K.; Volney, B.; Casteras, J.; Gabryszewski, S.J.; Volkman, S.K.; Wirth, D.F.;
Legrand, E.; Fidock, D.A.; et al. Adaptive evolution of malaria parasites in French Guiana: Reversal of
chloroquine resistance by acquisition of a mutation in pfcrt. Proc. Natl. Acad. Sci. USA 2015, 112, 11672–11677.
[CrossRef] [PubMed]
85. Nsanzabana, C.; Djalle, D.; Guérin, P.J.; Ménard, D.; González, I.J. Tools for surveillance of anti-malarial drug
resistance: An assessment of the current landscape. Malar. J. 2018, 17, 75. [CrossRef]
86. Nsanzabana, C.; Ariey, F.; Beck, H.-P.; Ding, X.C.; Kamau, E.; Krishna, S.; Legrand, E.; Lucchi, N.; Miotto, O.;
Nag, S.; et al. Molecular assays for antimalarial drug resistance surveillance: A target product profile. PLoS
ONE 2018, 13, e0204347. [CrossRef]
87. Hastings, I.M.; Watkins, W.M.; White, N.J. The evolution of drug-resistant malaria: The role of drug
elimination half-life. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2002, 357, 505–519. [CrossRef]
88. Maiga, H.; Lasry, E.; Diarra, M.; Sagara, I.; Bamadio, A.; Traore, A.; Coumare, S.; Bahonan, S.; Sangare, B.;
Dicko, Y.; et al. Seasonal Malaria Chemoprevention with Sulphadoxine-Pyrimethamine and Amodiaquine
Selects Pfdhfr-dhps Quintuple Mutant Genotype in Mali. PLoS ONE 2016, 11, e0162718. [CrossRef]
89. Zuber, J.A.; Takala-Harrison, S. Multidrug-resistant malaria and the impact of mass drug administration.
Infect. Drug Resist. 2018, 11, 299–306. [CrossRef] [PubMed]
90. Tun, K.M.; Jeeyapant, A.; Myint, A.H.; Kyaw, Z.T.; Dhorda, M.; Mukaka, M.; Cheah, P.Y.; Imwong, M.;
Hlaing, T.; Kyaw, T.H.; et al. Effectiveness and safety of 3 and 5 day courses of artemether–lumefantrine
for the treatment of uncomplicated falciparum malaria in an area of emerging artemisinin resistance in
Myanmar. Malar. J. 2018, 17, 258. [CrossRef] [PubMed]
91. Priotto, G.; Kabakyenga, J.; Pinoges, L.; Ruiz, A.; Eriksson, T.; Coussement, F.; Ngambe, T.; Taylor, W.R.J.;
Perea, W.; Guthmann, J.-P.; et al. Artesunate and sulfadoxine-pyrimethamine combinations for the
treatment of uncomplicated Plasmodium falciparum malaria in Uganda: A randomized, double-blind,
placebo-controlled trial. Trans. R. Soc. Trop. Med. Hyg. 2003, 97, 325–330. [CrossRef]
92. Mutabingwa, T.K.; Anthony, D.; Heller, A.; Hallett, R.; Ahmed, J.; Drakeley, C.; Greenwood, B.M.;
Whitty, C.J.M. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate,
and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: A four-arm
randomised effectiveness trial. Lancet 2005, 365, 1474–1480. [CrossRef]
93. Taylor, S.M.; Parobek, C.M.; Aragam, N.; Ngasala, B.E.; Mårtensson, A.; Meshnick, S.R.; Juliano, J.J. Pooled
deep sequencing of Plasmodium falciparum isolates: An efficient and scalable tool to quantify prevailing
malaria drug-resistance genotypes. J. Infect. Dis. 2013, 208, 1998–2006. [CrossRef] [PubMed]
94. Nag, S.; Dalgaard, M.D.; Kofoed, P.-E.; Ursing, J.; Crespo, M.; Andersen, L.O.; Aarestrup, F.M.; Lund, O.;
Alifrangis, M. High throughput resistance profiling of Plasmodium falciparum infections based on custom
dual indexing and Illumina next generation sequencing-technology. Sci. Rep. 2017, 7, 2398. [CrossRef]
[PubMed]
95. Talundzic, E.; Ravishankar, S.; Kelley, J.; Patel, D.; Plucinski, M.; Schmedes, S.; Ljolje, D.; Clemons, B.;
Madison-Antenucci, S.; Arguin, P.M.; et al. Next-Generation Sequencing and Bioinformatics Protocol for
Malaria Drug Resistance Marker Surveillance. Antimicrob. Agents Chemother. 2018, 62, e02474-17. [CrossRef]
Trop. Med. Infect. Dis. 2019, 4, 26 11 of 11
96. Hooft van Huijsduijnen, R.; Wells, T.N. The antimalarial pipeline. Curr. Opin. Pharmacol. 2018, 42, 1–6.
[CrossRef]
97. Ashley, E.A.; Phyo, A.P. Drugs in Development for Malaria. Drugs 2018, 78, 861–879. [CrossRef]
98. Worldwide Antimalarial Resistance Network (WWARN) AL Dose Impact Study Group. The effect of dose on
the antimalarial efficacy of artemether-lumefantrine: A systematic review and pooled analysis of individual
patient data. Lancet Infect. Dis. 2015, 15, 692–702. [CrossRef]
99. Kloprogge, F.; Workman, L.; Borrmann, S.; Tékété, M.; Lefèvre, G.; Hamed, K.; Piola, P.; Ursing, J.; Kofoed, P.E.;
Mårtensson, A.; et al. Artemether-lumefantrine dosing for malaria treatment in young children and pregnant
women: A pharmacokinetic-pharmacodynamic meta-analysis. PLoS Med. 2018, 15, e1002579. [CrossRef]
[PubMed]
100. Ursing, J.; Kofoed, P.-E.; Rodrigues, A.; Blessborn, D.; Thoft-Nielsen, R.; Björkman, A.; Rombo, L.
Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of
Plasmodium falciparum infection in Guinea-Bissau: A randomized trial. J. Infect. Dis. 2011, 203, 109–116.
[CrossRef] [PubMed]
101. Ursing, J.; Rombo, L.; Bergqvist, Y.; Rodrigues, A.; Kofoed, P.-E. High-Dose Chloroquine for Treatment of
Chloroquine-Resistant Plasmodium falciparum Malaria. J. Infect. Dis. 2016, 213, 1315–1321. [CrossRef]
[PubMed]
102. Dipanjan, B.; Shivaprakash, G.; Balaji, O. Triple Combination Therapy and Drug Cycling—Tangential
Strategies for Countering Artemisinin Resistance. Curr. Infect. Dis Rep. 2017, 19, 25. [CrossRef] [PubMed]
103. Dini, S.; Zaloumis, S.; Cao, P.; Price, R.N.; Fowkes, F.J.I.; van der Pluijm, R.W.; McCaw, J.M.; Simpson, J.A.
Investigating the Efficacy of Triple Artemisinin-Based Combination Therapies for Treating Plasmodium
falciparum Malaria Patients Using Mathematical Modeling. Antimicrob. Agents Chemother. 2018, 62, e01068-18.
[CrossRef] [PubMed]
104. Rossi, G.; De Smet, M.; Khim, N.; Kindermans, J.-M.; Menard, D. Emergence of Plasmodium falciparum
triple mutant in Cambodia. Lancet Infect. Dis. 2017, 17, 1233. [CrossRef]
105. Wojnarski, M.; Lin, J.; Gosi, P.; Spring, M.; Vanachayangkul, P.; Boonyalai, N.; Kuntawunginn, W.;
Chaisatit, C.; Kirativanich, K.; Saingam, P.; et al. The emergence of multidrug resistant malaria parasites
in Southeast Asia and implications on future malaria treatment Itinerary. In Proceedings of the ASTMH
Annual Meeting, New Orleans, LA, USA, 28 October–1 November 2018.
106. Najer, A.; Palivan, C.G.; Beck, H.-P.; Meier, W. Challenges in Malaria Management and a Glimpse at Some
Nanotechnological Approaches. Adv. Exp. Med. Biol. 2018, 1052, 103–112. [PubMed]
107. Walvekar, P.; Gannimani, R.; Govender, T. Combination drug therapy via nanocarriers against infectious
diseases. Eur. J. Pharm. Sci. 2019, 127, 121–141. [CrossRef] [PubMed]
108. Bakshi, R.P.; Tatham, L.M.; Savage, A.C.; Tripathi, A.K.; Mlambo, G.; Ippolito, M.M.; Nenortas, E.;
Rannard, S.P.; Owen, A.; Shapiro, T.A. Long-acting injectable atovaquone nanomedicines for malaria
prophylaxis. Nat. Commun. 2018, 9, 315. [CrossRef]
© 2019 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
